PubMed · 2013 · 53 citations · 29 references
MedicineOncologyPathologyGlial BiologyMolecular OncologyNeuro-oncologyBrain TumorsCancer Stem CellsGlial Cell BiologyGlioblastomaLysosome BiologyNeuro-oncologic PathologyAstrocytoma PathologyCancer Cell ApoptosisGlioblastoma Therapeutic ResistanceImmunofluorescence AssaysLysosome-associated Membrane ProteinsTherapy-resistant Cancer Stem CellsTumor Grade AssessmentTumor Grade Classification
Targeting of lysosomes is a novel therapeutic anti-cancer strategy for killing the otherwise apoptosis-resistant cancer cells. Such strategies are urgently needed for treatment of brain tumors, especially the glioblastoma, which is the most frequent and most malignant type. The aim of the present study was to investigate the presence of lysosomes in astrocytic brain tumors focussing also on the therapy resistant tumor stem cells. Expression of the lysosomal marker LAMP-1 (lysosomal-associated membrane protein-1) was investigated by immunohistochemistry in 112 formalin fixed paraffin embedded astrocytomas and compared with tumor grade and overall patient survival. Moreover, double immunofluorescence stainings were performed with LAMP-1 and the astrocytic marker GFAP and the putative stem cell marker CD133 on ten glioblastomas. Most tumors expressed the LAMP-1 protein in the cytoplasm of the tumor cells, while the blood vessels were positive in all tumors. The percentage of LAMP-1 positive tumor cells and staining intensities increased with tumor grade but variations in tumors of the same grade were also found. No association was found between LAMP-1 expression and patient overall survival in the individual tumor grades. LAMP-1/GFAP showed pronounced co-expression and LAMP-1/CD133 was co-expressed as well suggesting that tumor cells including the proposed tumor stem cells contain lysosomes. The results suggest that high amounts of lysosomes are present in glioblastomas and in the proposed tumor stem cells. Targeting of lysosomes may be a promising novel therapeutic strategy against this highly malignant neoplasm.
29
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Roger Stupp, Warren Mason, Martin J. van den Bent et al. · New England Journal of Medicine · 2005 · 21.6K citations · Full text
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Shideng Bao, Qiulian Wu, Roger E. McLendon et al. · Nature · 2006 · 6.4K citations
Medicine, Cancer Biology, Oncology +16
Identification of a cancer stem cell in human brain tumors.
Sheila K. Singh, Ian D. Clarke, Mizuhiko Terasaki et al. · PubMed · 2003 · 4.9K citations
Medicine, Cell Biology, Oncology +17
Cancerous stem cells can arise from pediatric brain tumors
Houman D. Hemmati, Ichiro Nakano, Jorge A. Lazareff et al. · Proceedings of the National Academy of Sciences · 2003 · 1.8K citations · Full text
Medicine, Cell Biology, Oncology +15